

Bibliographie : Cannabinoïdes et autismes / TED / psychoses infantiles.

Dr Christian Sueur, GRECC, avril 2020.

1. ARAN A., CASSUTO H., LUBOTZKY A., WATTAD N., HAZAN E.: Brief Report : Cannabidiol-Rich cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems - A Retrospective Feasibility Study, *Journal of Autism and Developmental Disorders*, 2018, Oct 31,
Doi : 10.1007/s10803-018-3808-2
2. ARAN A., EYLON M., HAREL M. et al. : Lower circulating endocannabinoid levels in children with autism spectrum disorder, *Molecular Autism*, 2019, 10, 2.
3. ARVEILLER J., SUEUR C. : Iatrogénèse et production du savoir sur les toxicomanies, *L'Évolution Psychiatrique*, 1989, 54, 2, 333-353.
4. BARCHEL D., STOLAR O., DE-HAAN T. et al. : Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities, *Frontiers in Pharmacology*, 2019, 9, 1521.
5. BAR-LEV SCHLEIDER L., MECHOULAM R., SABAN N. et al. : Real life experience of medical cannabis treatment in autism : Analysis of safety and efficacy, *Scientific Reports*, 2019, 9, 200.
6. BARNES G., SULLIVAN J., SEARS L. et al. : Safety and tolerability of GWP42006 (CBDV) in subjects with drug resistant epilepsy and autism, Presented at : *American Epilepsy Society Annual Meeting*, New Orleans, LA, November 30-December 4, 2018, Poster 3.288.
7. BELZUNG C., LEMAN S., VOUC'H, ANDRES C. : Rodents model for autism : a critical review, *Drug Discovery Today : Disease Models*, 2005, 2, 93-101.
8. BHATTACHARYYA S. : Cannabidiol As A Treatment In Different Stages Of Psychosis- Efficacy And Mechanisms, *Schizophrenia Bulletin*, 2018, 44, (suppl_1), S27-S27.
9. BIH C.I. et al. : Molecular targets of cannabidiol in neurological disorders, *Neurotherapeutics*, 2015, 12, 4, 699-730.
10. BOU KHALIL R. : Would some cannabinoids ameliorate symptoms of autism ?, *European Child and Adolescent Psychiatry*, 2012, 21, 237-238.
11. BRIGIDA A.L., SCHULTZ S., CASCONE M. et al. : Endocannabinoid Signal Dysregulation in Autism Spectrum Disorders : A Correlation Link between Inflammatory State and Neuro-Immune Alterations, *International Journal of Molecular Sciences*, 2017, 18, 1425, 13 p.
12. BUSQUETS-GARCIA A., GOMIS-GONZALES M., GUEGAN T. et al. : Targeting the endocannabinoid system in the treatment of fragile X syndrome, *Nature Medicine*, 2013, 19, 5, 603-607.
13. CAMPOS A.C. et al. : Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders, *Frontiers in Pharmacology*, 2017.
14. CAREAGA M., Van De WATER J., ASHWOOD P. : Immune dysfunction in autism : a pathway to treatment, *Neurotherapeutics*, 2010, 7, 3, 283-292.

15. CAREAGA M., ASHWOOD P.: Autism spectrum disorder : from immunity to behavior, *Methods in Molecular Biology*, 2012, 934, 219-240.
16. CHAKRABARTI B., PERSICO A., BATTISTA N. et al. : Endocannabinoid signaling in autism, *Neurotherapeutics*, 2015, 12, 837-847.
17. CONSROE P., SANDYK R.: Potential role of cannabinoids for therapy of neurological disorders, in Murphy L., Bartke A. eds, *Marijuana/Cannabinoids, Neurobiology and Neurophysiology*, Boca Raton, CRC Press, 1992, 459, 524.
18. CONSROE P.: Brain Cannabinoid systems as targets for the therapy of neurological disorders, *Neurobiological Diseases*, 1998, 5, 534-541.
19. DEVINSKY O., CROSS J.H., LAUX L. et al. : Trial of Cannabidiol for drug-resistant seizures in the Dravet Syndrome, *New England Journal of Medicine*, 2017, 376, 2011-2020.
20. Di MARZO V, MELCK D., BISOGNO T et al. : Endocannabinoids : endogenous cannabinoid receptor ligands with neuromodulatory action, *Trends in Neurosciences*, 1998, 21, 521-528.
21. FOGACA M.V. et al. : Cannabinoids, Neurogenesis and Antidepressant Drugs : is there a Link ?, *Current Neuropharmacology*, 2013, 11, (3), 263-275.
22. FOLDY C., MALENKA R.C., SUDHOFF T.C. : Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling, *Neuron*, 2013, 78, 3, 498-509.
23. GAETANI S. et al. : The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs, *International Review of Neurology*, 2009, 85, 57-72.
24. GARBETT K., EBERT P.J., MITCHELL A. et al. : Immune transcriptome alterations in the temporal cortex of subjects with autism, *Neurobiology of Disease*, 2008, 30, 303-311.
25. GRINSPOON L. : A Novel Approach to the Symtomatic Treatment of Autism, *O'Shaughnessy's*, summer 2010.
26. GROTHENHERMEN F. : Les cannabinoïdes et le système des endocannabinoïdes, *Cannabinoids*, 2006, 1, 1, 10-15.
27. GROTHENHERMEN F. : Chanvre en Médecine. Redécouverte d'une plante médicinale. Guide pratique des applications thérapeutiques du Cannabis, du THC et du CBD, Edition Solanacée, 2017.
28. GROTHENHERMEN F. : CBD. Un cannabinoïde au vaste potentiel thérapeutique, Edition Solanacée, Suisse, 2018, p 14.
29. GU B. : Cannabidiol provides viable treatments opportunity for multiple neurological pathologies of autism spectrum disorder, *Global Drugs and Therapeutics*, 2017.
Doi : 10.15761/GTD.1000134
30. GU B., ..., CARNEY P.R., PHILPOT B.D. : Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice, *Journal of Clinical Investigation*, 2019, 129, (12), 5462-5467.
Doi : 10.1172/JCI130419
31. HABIB S.S., AL-REGAIEY K., BASHIR S., IQBAL M. : Role of Endocannabinoids on Neuroinflammation in Autism Spectrum Disorder Prevention, *Journal of Clinical and Diagnostic Research*, 2017, 11, 6, 3p.
32. HADLAND S.E., KNIGHT J.R., HARRIS S.K. : Medical Marijuana : Review of the Science and Implications for Developmental Behavioral Pediatric Practice, *Journal of Developmental and Behavioral Pediatrics*, 2015, 36, 2, 115-123.

33. HAHN B.: The Potential of Cannabidiol Treatment for Cannabis Users with recent-onset psychosis, *Schizophrenia Bulletin*, 2018, 44, (1), 46-53.
34. HAUSMAN-KEDEM M., MENASCU S., KRAMER U.: Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study, *Brains & Development*, 2018, in press.
35. HOSIE S., MALONE D.T., LIU S. et al. : Altered amygdala excitation and CB1 receptor modulation of aggressive behavior in the neuroligin-3R451C mouse model of autism, *Frontiers in Cellular Neuroscience*, 2018, 12, 234.
36. IFFLAND K., GROTHENHERMEN F.: An update on safety and side effects of Cannabidiol : a review of clinical data and relevant animal studies, *Cannabis and Cannabinoid Research*, 2017, 2, 1, 139-154.
37. INGOLD F.R., SUEUR C., KAPLAN C.: Contribution à une exploration des propriétés thérapeutiques du Cannabis, *Annales Médico-Psychologiques*, 2015, 173, 5, 453-459.
38. IUVONE et al.: Neuroprotective effect of Cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells, *Journal of Neurochemistry*, 2004, 89, 1, 134-141.
39. JIANG W. et al.: Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic and antidepressant-like effects, *Journal of Clinical Investigation*, 2005, 115, (11), 3104-3116.
40. JUNG K.M., SEPERS M., PIOMELLI D., O.J. MANZONI et al.: Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome, *Nature Communications*, 2012, 3, 1080.
41. KARANIAN D.A., KARIM S.L., WOOD J.T., WILLIAMS J.S., et al. : Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage, *Journal of Pharmacology and Experimental Therapeutics*, 2007, 322, 3, 1059-1066.
42. KARHSON D.S. et al. : Plasma anandamide concentrations are lower in children with autism spectrum disorder, *Molecular Autism*, 2018, 12, 9, 18.
43. KERR D.M., DOWNEY L., CONBOY M. et al. : Alterations in the endocannabinoid system in the rat valproic acid model of autism, *Behavioural Brain Research*, 2013, 249, 124-132.
44. KOPPEL B.S., BRUST J.C., FIFE T. et al. : Systematic review : efficacy and safety of medical marijuana in selected neurologic disorders : report of the Guideline Development Subcommittee of the American Academy of Neurology, *Neurology*, 2014, 82, 1556-1563.
45. KRUGER T., CHRISTOPHERSEN E. : An Open Label Study of the Use of Dronabinol (Marinol) in the Management of Treatment-resistant Self-Injurious Behavior in 10 Retarded Adolescent Patients, *Journal of Developmental and Behavioral Pediatrics*, 2006, 27, 5, 433.
46. KURZ R., BLAAS K. : Use of dronabinol (delta-9-THC) in autism : A prospective single-case-study with an early infantile autistic child, *Cannabinoids*, 2010, 5, 4, 4-6.
47. LAFUENTE H., ALVAREZ F.J., PAZOS M.R. et al. : Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia-ischemia in newborn pigs, *Pediatric Research*, 2011, 70, 272-277.
48. LAPRAIRIE R.B., BAGHER A.M. et al. : Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor, *British Journal of Pharmacology*, 2015, 172, 20, 4790-4805.

49. LEWEKE F.M. et al. : Cannabidiol as an antipsychotic agent, *European Psychiatry*, 2007, 22, 1.
50. LEWEKE F.M., PIOMELLI D. et al. : Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia, *Translational Psychiatry*, 2012, 2, 3, e94.
51. LEWEKE F.M., MUELLER J.K., LANGE B., FRITZ S. et al. : Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia : Implications for Pharmacological Intervention, *CNS Drug*, 18 July 2018, doi.org/10.1007/s40263-018-0539-z.
52. LI X., CHAUHAN A., SHEIKH A.M., PATIL S. et al. : Elevated immune response in the brain of autistic patients, *Journal of Neuroimmunology*, 2009, 207, (1-2), 111-116.
53. MANERA C., ARENA C., CHICCA A. : Synthetic cannabinoid receptor agonist and antagonists : implication in CNS disorders, *Recent Patents on CNS Drug Discovery*, 2015, 10, 2 142-156.
54. MARTIN H.G.S., NEUHOFER D., MANZONI O.J.J. : The Endocannabinoid System in Fragile X Syndrome, Chapter 12, in « *Fragile X Syndrome – From Genetics to Targeted Treatment* », 2017, 241-259.
Doi : 10.1016/B978-0-12-804461-2.00012-3
55. McGUIRE P., ROBSON P. et al. : Cannabidiol (CBD) as an adjunctive Therapy in Schizophrenia : A multicenter Randomized Controlled Trial, *American Journal of Psychiatry*, 2018 March, 175, 3.
56. MEAD J., ASHWOOD P. : Evidence supporting an altered immune response in ASD, *Immunology Letters*, 2015, 163, 1, 49-55.
57. MECHA M., MECHOULAM R. et al. : Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress, *Cell Death and Disease*, 2012, 3.
58. MELANCIA F., SCHIAVI S., SERVADIO M. et al. : Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signaling, *British Journal of Pharmacology*, 2018, 175, 3699–3712.
59. MILES K. : Marijuana-like Chemical May Help Autism and X Fragile Syndrome Symptoms, 2012.
60. MORGAN C.J.A., CURRAN V. : Effects of cannabidiol on schizophrenia-like symptoms in peoples who use cannabis, *British Journal of Psychiatry*, 2008, 192, 306-307.
61. NADAL X., Del RIO C., CASANO S., MUÑOZ E. et al. : Tetrahydrocannabinolic acid is a potent PPAR γ agonist with neuroprotective activity, *British Journal of Pharmacology*, 2017, 174, 23, 4263-4276, doi : 10.1111/bph.14019.
62. NAGAYAMA T. et al. : Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures, *Journal of Neurosciences*, 1999, 19, 2987-2995.
63. NIELSEN S., GERMANOS R., WEIER M. et al. : The use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis : a systematic Review of Reviews, *Current Neurology and Neuroscience Reports*, 2018, 18, 8, 12 pp.
64. ONAIVI E.S., BENNO R., HALPERN T., MEHANOVIC M. et al. : Consequences of Cannabinoid and Monoaminergic System Disruption in a Mouse model of Autism Spectrum Disorders, *Current Neuropharmacology*, 2011, 9, 209-214.

65. PAZOS M.R., MOHAMMED N., LAFUENTE H. et al : Mechanisms of cannabidiol neuroprotection in hypoxi-ischemic newborn pigs : role of 5HT(1A) and CB2 receptors, *Neuropharmacology*, 2013, 71, 282-291.
66. PERTWEE R.G. : The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids : Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin, *British Journal of Pharmacology*, 2008, 153, 2, 199-215.
67. PERTWEE R.G. : Receptors and Channels Targeted by Synthetics Cannabinoid receptor agonists and antagonists, *Current Medicinal Chemistry*, 2010, 17, 14, 1360-1381.
68. PERTWEE R. : Cannabinoids and multiple sclerosis, *Pharmacology & Therapeutics*, 2002, 95, 2, 165-174.
69. PERTWEE R.G. editor : *Handbook of Cannabis*, Oxford University Press, United Kingdom, 2016.
70. POLEG S., GOLUBCHIK P., OFFEN D. et al. : Cannabidiol as a suggested candidate for treatment of autism spectrum disorder, *Progress in Neuropsychopharmacology and Biological Psychiatry*, 2019, 89, 90-96.
71. PRETZSCH C.M., FREYBERG Jan, VOINESCU B., LYTHGOE D., HORDER J., MENDEZ M.A., WICHERS R., AJRAM L., IRVIN G., HEASMAN M., EDDEN R.A.E., WILLIAMS S., MURPHY D.G.M., DALY E., McALONAN G.M. : Effects of cannabidiol on brain excitation and inhibition systems ; a randomized placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder, *Neuropsychopharmacology*, 2019, 0, 1-8.
Doi : 10.1038/s41386-019-0333-8
72. RANGANATHAN M., de SOUZA D. et al. : Efficacy of Cannabidiol in the treatment of early psychosis, *Sixth Biennial SIRS Conference*, 2018.
73. RIMLAND B., Marijuana thérapeutique : un traitement intéressant pour l'autisme?, *Autism Research Review International*, 2003, 17, 1 3-4.
74. ROHLEDER C., MULLER J. K., LANGE B., LEWEKE F.M. : Cannabidiol as a Potential New Type of an Antipsychotic. A critical Review of the Evidence, *Frontiers in Pharmacology*, 2016.
75. SALA M., BRAIDA D., LENTINI D. et al. : Pharmacological rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice : a neurobehavioral model of autism, *Biological Psychiatry*, 2011, 69, 875-882.
76. SEEMAN P. : Cannabidiol is a partial agonist at dopamine D2-High receptors, predicting its antipsychotic clinical dose, *Translational Psychiatry*, 2016.
77. SCUDERY C. ET AL. : Cannabidiol in medicine : a review of its therapeutic potential in CNS disorders, *Phytotherapy Research*, 2009, 23, 5, 597-602.
78. SCHULTZ S., SINISCALCO D. : Endocannabinoid system involvement in autism spectrum disorder : An overview with potential therapeutic applications, *Molecular Sciences*, 2019.
Doi : 10.3934/molsci.2019.1.27
79. SINISCALCO D., SAPONE A., GIORDANO C et al. : Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders, *Journal of Autism and Developmental Disorders*, 2013, 43, 2686-2695.
80. SUEUR C. : État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21^e siècle, *Psychotropes*, 2017, 23, 3, 125-163.

81. SUEUR C., INGOLD F.X. : Les Cannabis thérapeutique en Neurologie et Psychiatrie, à paraître, *GRECC*, 2019.
82. TARTAGLIA N., BONN-MILLER M., HAGERMAN R. : Treatment of Fragile X Syndrome with Cannabidiol : A Case Series study and brief Review of the Literature, *Cannabis and Cannabinoid Research*, 2019, 4, 1, Doi : 10.1089/can.2018.0053
83. VARGAS D.L., NASCIMBENE C., KRISHNAN C., ZIMMERMAN A.W., PARDO C.A. : Neuroglial activation and neuroinflammation in the brain of patients with autism, *Annals of Neurology*, 2005, 57, 1, 67-81.
84. VEZYROGLOU K., CROSS J.H. : Targeted Treatment in Childhood Epilepsy Syndromes, *Epilepsy, Current treatment Options Neurology*, 2016, 18, 29, 12 pp.
85. WEI D., LEE D., COX C., KARSTEN C., PIOMELLI D. et al. : Endocannabinoid signaling mediates oxytocin-driven social reward, *PNAS*, 2015, 112, 5, 14084-14089.
86. XU N., LI X., ZHONG Y. : Inflammatory cytokines : potential biomarkers of immunologic dysfunction in autism spectrum disorders, *Mediators of Inflammation*, 2015.
87. ZAMBERLETTI E., GABAGLIO M., PAROLARO D. : The endocannabinoid system and autism apectrum disorders: Insights from animal models. *Int J Mol Sci*, 2017, 18, pii: E1916.
88. ZUARDI A.W. et al. : Effects of cannabidiol in animal models predictive of antipsychotic activity, *Psychopharmacology*, 1991, 104, 2, 260-264.
89. ZUARDI A.W. et al. : Antipsychotic effects of cannabidiol, *Journal of Clinical Psychiatry*, 1995, 56, 10, 485-486.
90. ZUARDI A.W. et al. : Cannabidiol monotherapy for treatment-resistant schizophrenia, *Journal of Psychopharmacology*, 2006, 20, 5, 683-686.
91. ZUARDI A.W. et al. : Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug, *Brazilian Journal of Medical and Biological Research*, 2006, 39, 421-429.
92. ZUARDI A.W., CRIPPA J.A.S. et al. : A critical review of the Antipsychotic Effects of Cannabidiol : 30 Years of a translational Investigation, *Current Pharmaceutical Design*, 2012, 18, 5131-5140.
93. ZUARDI A.W., de SOUZA CRIPPA J.A., HALLACK J.A. et al. : The Anxiolytic Effects of Cannabidiol (CBD), December 2017.

<https://www.cbc.ca/news/canada/toronto/mom-of-daughter-with-severe-autism-says-cannabis-therapy-is-heaven-sent-1.4440936>

<https://eu.usatoday.com/story/news/world/2017/04/25/marijuana-pot-treatment-children-autism-cannabis-oil/100381156>

<https://ansm.sante.fr/S-informer/Travaux-de-l-Agence-Europeenne-des-Medicaments-EMA-Comite-des-medicaments-orphelins-COMP/Avis-et-recommandations-du-Comite-des-medicaments-orphelins-COMP-de-l-Agence-europeenne-des-medicaments-EMA-de-septembre-2014-Point-d-information>

<https://ansm.sante.fr/S-informer/Travaux-de-l-Agence-Europeenne-des-Medicaments-EMA-Comite-des-medicaments-orphelins-COMP/Avis-et-recommandations-du-Comite-des-medicaments-orphelins-COMP-de-l-Agence-europeenne-des-medicaments-EMA-de-juin-2015>

ClinicalTrials.gov : Cannabidivaricin (CBDV) versus placebo in children with autism spectrum disorder (ASD) NCT03202303, Accessed November 10, 2019.